Application of salvianolate in preparation of kidney protective agent drugs

A technology of salvianolate and protective agent, which is applied in the application field of salvianolate and salvianolate magnesium in the preparation of renal protectant drugs, and can solve the problem that there are no reports to study the influence of salvianolate magnesium on renal microcirculation, etc. problem, to achieve the effect of great clinical application value

Inactive Publication Date: 2013-12-04
SHANGHAI GREEN VALLEY PHARMA +1
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far there is no report on the effect of magnesium

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of salvianolate in preparation of kidney protective agent drugs
  • Application of salvianolate in preparation of kidney protective agent drugs
  • Application of salvianolate in preparation of kidney protective agent drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Effects of Salvia Magnesium Acetate on Microcirculation of Renal Cortex in SHR Rats

[0040] The kidneys play a decisive role in maintaining the body's water-salt balance. A highly regulated microcirculation and homeostasis are essential for the maintenance of optimal renal function. The renal microcirculation requires an intrinsic dynamic response to maintain an appropriate renal environment. This experiment was to study the effect of magnesium salvianolic acid B on renal microcirculation and hemorheology in hypertensive rats.

[0041] 1. Materials and Methods

[0042] 1.1 Reagents and medicines

[0043] Magnesiumlithospermate B (MLB; 95% purity) was produced by Shanghai Lvgu Pharmaceutical Co., Ltd. and was light brown in color. Prepare with normal saline before use. Inject 5ml of normal saline into the vial to dilute and suck it out, then inject the diluted liquid into 250ml of normal saline. All reagents are commercially available analytically pure products.

...

Embodiment 4

[0069] Preventive and therapeutic effect of salvianolate for injection on renal injury induced by contrast medium

[0070] Salvianolate for injection is produced by Shanghai Green Valley Pharmaceutical Co., Ltd., and its specifications are 50mg per bottle (containing 40mg of salvia acetic acid magnesium), 100mg per bottle (containing 80mg of salvia acetic acid magnesium), and 200mg per bottle (containing Magnesium 160mg). The implementation standard is the State Food and Drug Administration standard YBZ09012005-2010Z.

[0071] The resulting data is as follows:

[0072] Table 3 List of positive (different) serum creatinine before treatment and after treatment (7 days after operation)

[0073]

[0074] Table 4 List of abnormal values ​​of serum creatinine 7 days after operation (μmol / L)

[0075]

[0076]

[0077] Note: "abnormal -" means that the abnormality has no clinical significance; "abnormal +" means that the abnormality has clinical significance

[0078] Tabl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of salvianolate in preparation of kidney protective agent drugs. A study on effects of injection-use salvianolate on acute myocardial perfusion in acute myocardial infarction direct PCI (percutaneous coronary intervention) and prognosis founds that: subjects using the injection-use salvianolate, compared with other group subjects, after use of a contrast agent, may not have severe kidney injuries, and the injection-use salvianolate has a kidney protective effect. The invention also provides the application of magnesium lithospermate B in preparation of the kidney protective agent drugs. Effects of the magnesium lithospermate B on kidney microcirculation and overall hemorheology are studied through use of spontaneously hypertensive rats. Experiments prove that the magnesium lithospermate B in physiological and pathological states both can dose-dependently improve kidney cortex microcirculation, and show that the kidney protective effect of the magnesium lithospermate B is realized through direct improvement of the kidney microcirculation, so that the salvianolate and the magnesium lithospermate B can be used for preparation of the drugs for the prevention and treatment of the kidney injures caused by the contrast agent. The application of the salvianolate in preparation of the kidney protective agent drugs has great clinical application value.

Description

technical field [0001] The invention relates to medicines, in particular to the application of salvianolate and magnesium acetate in the preparation of nephroprotectant medicines. Background technique [0002] "Salvianolate for injection" is a Class II new drug of traditional Chinese medicine researched and developed by Shanghai Institute of Materia Medica, Chinese Academy of Sciences for 13 years. It obtained the new drug certificate for raw materials and preparations in May 2005, and is produced by Shanghai Green Valley Pharmaceutical Co., Ltd. The product was put into production in 2006. Salvianolate for injection can reduce no-reflow and improve myocardial microcirculation in patients with acute myocardial infarction undergoing direct PCI. Improve recurrent angina, heart failure, death, etc. The study of "Salvianolate for Injection" is the first to clarify that Salvianolate with magnesium acetate as the main component is the most important effective active ingredient i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/343A61P13/12
Inventor 任贤徐向阳王逸平谢楠
Owner SHANGHAI GREEN VALLEY PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap